

Glypicans shield the Wnt lipid moiety to enable signalling at a distance

Ian J. McGough^{1*}, Luca Vecchia^{2*}, Benjamin Bishop², Tomas Malinauskas², Karen Beckett¹, Dhira Joshi¹, Nicola O'Reilly¹, Christian Siebold², E. Yvonne Jones^{2@} and Jean-Paul Vincent^{1,@}

* Equivalent contribution

@ Equivalent senior authors for correspondence

¹ The Francis Crick Institute, London NW1 1AT, UK

² Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.

Running Title: **Wnt solubilisation by glypicans**

Keywords: Wnt, palmitoleate, glypicans, crystal structure, morphogens

Summary

A relatively small number of proteins have been suggested to act as morphogens, signalling molecules that spread within tissues to organize cell fate specification during development and tissue repair. Among them are Wnt proteins, which carry a palmitoleate moiety that is essential for signalling activity¹⁻³. How can a hydrophobic lipoprotein spread in the aqueous extracellular space? A variety of mechanisms, some invoking lipoprotein particles, exosomes or a specific chaperone, have been proposed to overcome this so-called Wnt solubility problem⁴⁻⁶. Here we provide evidence against these models and show that the Wnt lipid is shielded by the core domain of a subclass of glypicans defined by the Dally-like protein (Dlp). Structural analysis shows that, in the presence of palmitoleated peptides, these glypicans change conformation to create a hydrophobic space. Thus, glypicans of the Dlp family protect the lipid of Wnts from the aqueous environment and serve as a reservoir from where Wnts can be handed over to signalling receptors.

Wnt proteins are lipidated¹, with a palmitoleate² appended to a conserved serine (Ser 209 in WNT3A). Crystal structures have shown how the Wnt palmitoleate contributes directly to engagement with the Frizzled receptor and hence signalling activity³. Despite being lipidated, and therefore hydrophobic, Wnts can act over several cell diameters, although the range may vary depending on the tissue. Long range action has been suggested to organize the anterior-posterior axis of *Xenopus* embryos⁷ while juxtacrine action could suffice in the mouse intestinal crypt⁸. Flies relying solely on membrane-tethered Wingless (the main Wnt in *Drosophila*) are morphologically normal, but suffer from a number of phenotypes including delayed development, sterility, and reduced food intake⁹(see also reference¹⁰). Even in wing precursors, where long range action is not essential for patterning, Wingless spreads over more than 10 cell diameters¹¹ and contributes to timely growth and full target gene activation⁹. Because extracellular Wingless is readily detectable in wing imaginal discs, they constitute a good tissue in which to study its spread in a physiological setting.

49

50 **Models of Wnt transport**

Earlier work has suggested that lipoprotein particles (LPPs) or exosomes could transport Wnt in the extracellular space^{4,5}. To test whether endogenously expressed Wingless interacts with these structures, we devised a trapping assay inspired by the morphotrap approach¹². A membrane-tethered anti-GFP nanobody (Vhh4-CD8) was used to capture GFP-Wingless expressed from a knock-in allele. This led to enrichment of GFP-Wingless at the surface of expressing cells (Extended Data Fig. 1a), but not of Lipophorin, a component of LPPs, or the ESCRT protein Hrs, a marker of exosomes (Extended Data Fig. 1b, c). A secreted form of Dlp (Dlp^{ΔGPI}), which is known to bind Wingless^{13,14}, served as a positive control (Extended Data Fig. 1d). Moreover, we found that GFP-Wingless trapped by Neurotactin-LaG16 (another morphotrap) had no effect on the distribution of HA-Wingless expressed from the other endogenous allele (Fig 1a). This result argues against transport mechanisms involving multiple Wingless molecules such as exosomes, LPPs, or micelles.

63

We next designed genetic tests to further assess the possible roles of exosomes and LPPs. As there is no specific way to prevent exosome formation, we inhibited the biogenesis of multivesicular bodies from where exosomes originate. This was achieved by expressing VPS4^{DN}, a dominant negative form of VPS4, which is required for the final step in the invagination of luminal vesicles. Within 8 hours of expression, ubiquitinated proteins

69 accumulated, as expected, but no impact on the distribution of extracellular Wingless could
70 be seen (Extended Data Fig. 2a). Similarly, the spread of Wingless appeared normal within
71 tissues lacking Hrs, another ESCRT component (Extended Data Fig. 2b). To assess the role
72 of LPPs, we modulated the activity of their receptors (Lpr1 and Lpr2) by gain and loss of
73 function manipulations. Overexpression of the Lpr2E isoform (for a period of 36 hours)
74 depleted available Lipophorin from the extracellular space (Extended Data Fig. 2c) but did
75 not impact extracellular Wingless levels (Extended Data Fig. 2d). Conversely, deletion of
76 both Lpr1 and Lpr2 also had no effect on extracellular or total Wingless, despite perturbing
77 LPP uptake (Extended Data Fig. 2e).

78

79 One alternative model for Wnt transport involves SWIM, a lipocalin that solubilizes
80 Wingless in S2 cell culture medium⁶. To confirm an initial RNAi-based assessment of
81 SWIM's role (Extended Data Fig. 3a), we generated a genomic deletion that removes the
82 entire coding region (*SWIM*^{KO}) (Extended Data Fig. 3b). Homozygotes, lacking all gene
83 function, were healthy and fertile with no apparent phenotype. Moreover, the distribution of
84 total and extracellular Wingless was indistinguishable in *SWIM*^{KO} homozygotes and control
85 wing imaginal discs (Extended Data Fig. 3c). No change in the Wingless target gene *Distal-*
86 *less* was observed (Extended Data Fig. 3c). We conclude that SWIM is entirely dispensable
87 for Wingless transport although we cannot exclude a possible redundant role, say in
88 combination with another lipocalin. In summary, our analysis so far has provided evidence
89 against all the previously proposed mechanisms of Wnt transport, except for that involving
90 cytonemes¹⁵, for which specific genetic tools are lacking. We therefore set out to re-
91 investigate the role of glypicans, a class of proteins known to modulate the extracellular
92 distribution of Wnt^{13,14}.

93

94 **A subset of glypicans bind the Wnt lipid**

95 Extensive genetic analysis has demonstrated the role of the *Drosophila* glypicans Dally and
96 Dlp in ensuring proper extracellular distribution of Wingless^{13,14,16}. Indeed, Wingless is
97 markedly reduced at the surface of cells lacking both glypicans (Extended Data Fig. 3d).
98 Mutations in *sulfateless*, which impair the addition of heparan sulfate (HS) chains on
99 glypicans, also lead to a strong reduction in extracellular Wingless, and phenocopy loss of
100 Wingless signalling¹⁶. This is consistent with Wnts binding HS chains¹⁷, which decorate both
101 Dlp and Dally. Intriguingly though, loss of Dlp has a more marked impact on extracellular
102 Wingless than loss of Dally (Fig. 1b, c). Dlp binding to Wingless has been reported to

involve two sites: one involving the HS chains and the other, the protein core¹³. We considered the possibility that the core site could mediate the elusive interaction that shields the palmitoleate of Wnt.

We first asked to what extent Wingless needs to be lipidated in order to bind Dlp *in vivo* by comparing the ability of overexpressed Dlp to trap palmitoleoylated and non-palmitoleoylated Wingless at the surface of imaginal discs cells. Dlp overexpressed in a stripe that transects the normal stripe of *wingless* expression duly trapped endogenous-level GFP-Wingless (Fig. 2a). By contrast, Dlp did not detectably trap GFP-Wingless[S239A], even though this unlipidated form of Wingless is secreted^{14,18,19} and trappable by Vhh4-CD8 (morphotrap) (Extended Data Fig. 4a). We next assessed whether Dlp has standalone palmitoleate-binding activity by measuring its interaction with palmitoleoylated and control unlipidated peptide (both biotinylated). Catalytically dead Notum, which has a marked preference for the palmitoleoylated peptide²⁰ served as a positive control. Dlp^{core} (the minimal globular protein core lacking the GPI anchor and HS chains) also bound preferentially to the palmitoleoylated peptide while Dally^{core} had no such activity (Extended Data Fig. 4b). Prompted by these findings, we purified Dlp^{core} and Dally^{core} and investigated their binding properties by biolayer interferometry (BLI). Dlp^{core} bound the palmitoleoylated version with sub-micromolar affinity (Fig. 2b and Extended Data Fig. 4c) but had no detectable affinity for the non-palmitoleoylated peptide (Extended Data Fig. 4d). Dally^{core} showed no measurable interaction with palmitoleoylated peptide (Fig. 2b). We conclude that Dlp, but not Dally, has palmitoleate-binding activity.

Sequence conservation shows that the six human glypicans can be distinguished according to their homology to Dlp or Dally. We expressed two of each class in wing imaginal discs. Of these, hGPC4 and hGPC6 (homologous to Dlp) trapped Wingless while hGPC3 and hGPC4 (homologous to Dally) did not (Fig. 2 and Extended Data Fig. 4e). Therefore, lipid binding activity seems to be a hallmark of the Dlp class of glypicans. Overexpressed Dlp has previously been shown to have biphasic activity in wing imaginal discs^{13,14}, inhibiting the high target gene *senseless*, but extending the range of the low target gene *distal-less*. This could be explained if Dlp competed with Frizzled for lipid binding (decreasing signalling) while at the same time promoting long range transport by shielding the Wingless lipid. Tellingly, hGPC4 and hGPC6, but not hGPC3 and hGPC5, displayed a similarly biphasic activity (Extended Data Fig. 5a, b). It appears therefore that human glypicans of the Dlp

family could modulate the extracellular behaviour of Wnts through their palmitoleate-binding activity.

Solubilisation of Wingless by glypicans

Soluble Wnt cannot be recovered from serum-free medium conditioned by Wnt-expressing cells^{1,6,21}. This is likely because of the absence of an activity that shields the palmitoleate. Indeed, addition of lipid-binding proteins, such as Afamin or SWIM, to the culture medium enables the release of soluble Wnt^{6,22}. To confirm the lipid-binding activity of Dlp and mammalian Dlp orthologs, we tested whether they too could solubilize Wingless. S2 cells were induced to co-express secreted forms of glypicans (lacking their membrane anchor, Δ GPI) and GFP-Wingless in serum-free medium. While Dlp ^{Δ GPI} allowed large amounts of GFP-Wingless to be recovered in the supernatant, Dally ^{Δ GPI} did not (Fig. 2d). A similar effect was seen upon addition of Dlp ^{Δ GPI} in the culture medium of GFP-Wingless-expressing cells (Extended Data Fig. 5c), showing that co-secretion is not needed for Dlp ^{Δ GPI} to solubilise Wingless. Similarly, secreted hGPC4 and hGPC6 solubilized GFP-Wingless while secreted hGPC3 and hGPC5 did not (Fig. 2e). Solubilization enables signalling since co-expression with Dlp was needed for transfected GFP-Wingless to activate a luciferase-based reporter (Extended Data Fig. 5d). Accordingly, an unidentified HSPG shown previously to stabilise Wnt activity²¹ is probably a Dlp-class glypican. We conclude that glypicans of the Dlp family bind palmitoleate and thus contribute to the release of signalling-competent Wnt.

Palmitoleate-bound conformation of Dlp

We set out to identify the molecular determinants of palmitoleate binding by the Dlp protein core. The crystal structure of Dlp^{core} has been reported previously²³ and structural comparison has suggested that its N-terminal region is distantly related to the extracellular cysteine-rich domain (CRD) of the Frizzled family of Wnt receptors²⁴. Given that the Frizzled CRD (Fzd^{CRD}) provides a groove-like binding site for palmitoleate³, we first looked for the equivalent groove in the uncomplexed (apo) structure of Dlp^{core}. Superposition of the structure of apo Dlp^{core} onto those of Fzd^{CRD} – Wnt complexes^{3,25} showed that, in Dlp, the CRD is more compact and the putative binding groove shallower (Extended Data Figure 6a-f). Notably, glypican CRDs contain an additional α -helix that is located transversally to the entrance of the groove, thereby blocking lipid insertion (Extended Data Figure 6g-h). This holds for structures of Dlp and hGPC1²⁶.

170
171 The groove-blocking helix of the glypican CRD architecture renders an analogy with the
172 palmitoleate-binding properties of the Frizzled CRDs untenable. We therefore sought to
173 discover the site of palmitoleate-binding in Dlp^{core} by direct experiment. We determined a
174 2.21 Å resolution crystal structure for Dlp^{core} in complex with a palmitoleoylated peptide.
175 The overall structure of uncomplexed Dlp^{core}²³ is conserved in the complex, with a global
176 mainchain RMSD of 1.98 Å (for 355 equivalent Cα pairs) (Fig. 3a). Some additional portions
177 of the Dlp^{core} N-terminal segment were visible. These include an α-helix, which we named
178 αH0 (for helix nomenclature see Extended Data Fig. 7a) and a 30-residue unstructured loop,
179 similar to that seen in the published structure of hGPC1²⁶. However, the region corresponding
180 to the palmitoleate-binding groove of Fzd^{CRD} remains occluded by the transversal α-helix
181 (αH1) (Extended Data Fig. 6g-h). Crucially, additional electron density, consistent with a
182 palmitoleate acyl chain (see Methods and Extended Data Fig. 8), was present on the opposite
183 side of the Dlp^{core}, in the so-called C-lobe²³. Well-ordered electron density revealed the acyl
184 chain, the ester bond with associated serine sidechain and the serine mainchain of the
185 palmitoleoylated peptide. The remainder of the peptide lacks a well-defined conformation in
186 the complexed structure. Most of the interactions between Dlp and the Wnt peptide are
187 hydrophobic and involve the palmitoleate, consistent with our biophysical and biochemical
188 data showing the interaction requires the lipid moiety.

189
190 Superposition of the apo and complexed Dlp^{core} structures revealed that palmitoleate binding
191 is associated with a conformational rearrangement in which helix αH9 and αH10 tilt away
192 from the opposing helix, αH1, to generate a substantial shift in position (~ 6 Å between apo
193 and complexed structures at P365). An analysis of lattice contacts with neighbouring
194 molecules indicated that the rearrangement was unlikely to result from the crystal
195 environment (see Methods). This movement opens a tunnel-like cavity to accommodate the
196 palmitoleate (Fig. 3b). The cavity is lined with hydrophobic residues contributed by six C-
197 lobe α-helices (L164, L165, F172 of αH1; F191, L194, F195, L198 of αH2; F216 of αH3;
198 L259, I263, F267 of αH5; I359, V363 of αH9 and L366 of αH10, see Fig. 3c). The sixteen-
199 carbon (C16) acyl chain of the palmitoleate adopts an extended conformation resembling
200 those reported for the Wnt-attached lipid in Fzd^{CRD} – Wnt complexes^{3,25}, but markedly
201 different from that observed for lipid-binding to Notum²⁰, which requires a kink in the
202 palmitoleate (at the C9-C10 *cis* double bond). Notably, the palmitoleate only occupies the

narrower, top part of the cavity generated by the conformational change in complexed Dlp^{core}, leaving substantial space in the bottom part of the cavity (Extended Data Fig. 7b).

Mutations impairing palmitoleate-binding

To functionally validate our structural findings, we designed Dlp mutants to interfere with Wnt binding (Fig. 3b, c). We initially aimed to hamper lipid insertion into the cavity either by introducing a bulky residue (S168M) at the entrance, or by engineering a disulphide bridge to prevent α H10 and α H1 from coming apart and hence locking Dlp in the closed, apo conformation (N367C on α H10 and M175C on α H1). As a first step, Fluorescence-detection Size Exclusion Chromatography (FSEC) was used to assess the binding of purified Dlp^{core} variants to bodipy 505/512-labelled palmitic acid. Dlp^{core} (as recognised by the 280nm protein peak) co-eluted with bodipy fluorescence, indicating binding and hence some level of promiscuity in its lipid-binding activity. As expected, binding to bodipy-palmitate was substantially reduced for both mutant proteins (Fig. 4a). These proteins were also impaired in their ability to trap endogenous Wingless *in vivo*, albeit to different extents; of the two, only the [N367C, M175C] mutation completely abrogated *in vivo* trapping while Dlp[S168M]^{AGPI} retained some activity (Fig. 4b). Accordingly, Dlp[S168M]^{AGPI} and Dlp[N367C, M175C]^{AGPI} were less efficient than wild type Dlp^{AGPI} at solubilising GFP-Wingless in culture medium (Fig. 4c). We further used the *in vivo* trapping assay to investigate the functional relevance of sequence differences between Dally and Dlp (Extended Data Fig. 9a). Mutations in Dlp to replace hydrophobic residues with polar ones (Dlp[F172T, F195Y]; FF/TY), or to introduce the putative glycosylation site of Dally (Dlp[R169E, T170N, Q171M, F172T]; RTQF/ENMT), reduced trapping, though not completely (Extended Data Fig. 9b). Dally mutations that remove the predicted glycosylation site and restore the hydrophobic F (Dally[E149R, N150T, M151Q, T152F]; ENMT/RTQF) did not confer lipid-binding activity. These results suggest that the difference in Wnt-binding activity between Dlp and Dally cannot be solely ascribed to residues at the entrance or within the tunnel. Since Dlp[N367C, M175C]^{AGPI} had no *in vivo* trapping activity (Fig. 4b), even at the high level of expression achieved by the Gal4 system, we suggest that the movement of α H10 relative to α H1, as observed in the crystal structure, is essential for tunnel formation and lipid-binding.

Discussion

Based on various lines of evidence against the possible roles of exosomes, lipoprotein particles and SWIM in the spread of Wingless, we re-examined the binding of Wingless to glypicans. We found that, of the two glypicans encoded by the *Drosophila* genome, Dlp, but not Dally, has palmitoleate-binding activity. This activity is conserved among human glypicans of the Dlp class and is not present among human homologs of Dally. We suggest that Dlp-class glypicans have evolved lipid-binding activity to shield the lipid of Wnts, and possibly, that of other signalling molecules such as palmitate and/or cholesterol on Hedgehog family members. As we showed, Dlp's core (devoid of HS chains) can sequester the palmitoleate moiety of Wnt peptides by forming a tunnel-like binding cavity. A combination of differences between Dlp and Dally, such as the nature of residues at the entrance and within the cavity, as well as structural features that allow α H9 and α H10 to shift relative to α H1, could account for the lipid-binding activity of Dlp-class glypicans.

Glypicans of the Dlp class are not the only extracellular lipid-binding proteins. For example, *Drosophila* Frizzled3, a decoy receptor of Wingless²⁷ has been shown to hold signalling-competent Wingless at the cell surface²⁸. And secreted Frizzled related proteins (sFRPs) are known to aid Wnt diffusion in vertebrates²⁹. Thus, a number of extracellular proteins have the capacity to shield the palmitoleate of Wnt. We suggest nevertheless that several features of Dlp-class glypicans make them particularly suitable for Wnt transport along epithelia. Their GPI anchor facilitates rapid diffusion within the cell membrane while ensuring retention in the plane of the epithelium. Moreover, dual binding, through long HS chains and the hydrophobic tunnel, could enable handover from one Dlp-class glypican to another facilitating cell-to-cell transfer (Extended Data Fig. 9c). At some frequency, Wnts would transfer from Dlp-class glypicans to Frizzled receptors to initiate signalosome assembly, as previously suggested (see Fig. 5D in reference¹⁴). Although Dally is not essential for Wingless activity in *Drosophila*, it must contribute since the phenotype of *dally dlp* double mutants is stronger than that of the single *dlp* mutant (partial redundancy)^{13,14,30,31}. It is likely that Dally-class glypicans bind Wnts via their HS chains. However, because they lack lipid-binding activity, the glypicans of this class would promptly off-load their cargo to a Frizzled receptor, thus serving only as co-receptors. Our results suggest that Dlp-class glypicans constitute an easily accessible reservoir of signalling-competent Wnt at the surface of signalling cells. In chick embryos, neural crest cells have been shown to carry and deliver

Wnts at a distance in a GPC4-dependent manner³², suggesting that this reservoir can be brought to distant sites by cell migration. Cytosomes, which are coated with glypicans³³ could similarly boost the mobility of the Wnt reservoir by allowing cell membranes carrying signalling-competent Wnt to reach distant sites more rapidly. The capacity of this reservoir could readily be modulated by changes in expression or activity of Dlp class glypicans, perhaps explaining why the range of Wnts differs in various contexts.

REFERENCES

- 1 Willert, K. *et al.* Wnt proteins are lipid-modified and can act as stem cell growth factors. *Nature* **423**, 448-452, doi:10.1038/nature01611 (2003).
- 2 Takada, R. *et al.* Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. *Dev Cell* **11**, 791-801, doi:10.1016/j.devcel.2006.10.003 (2006).
- 3 Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C. & Garcia, K. C. Structural basis of Wnt recognition by Frizzled. *Science* **337**, 59-64, doi:10.1126/science.1222879 (2012).
- 4 Panakova, D., Sprong, H., Marois, E., Thiele, C. & Eaton, S. Lipoprotein particles are required for Hedgehog and Wingless signalling. *Nature* **435**, 58-65, doi:10.1038/nature03504 (2005).
- 5 Gross, J. C., Chaudhary, V., Bartscherer, K. & Boutros, M. Active Wnt proteins are secreted on exosomes. *Nat Cell Biol* **14**, 1036-1045, doi:10.1038/ncb2574 (2012).
- 6 Mulligan, K. A. *et al.* Secreted Wingless-interacting molecule (Swim) promotes long-range signaling by maintaining Wingless solubility. *Proc Natl Acad Sci U S A* **109**, 370-377, doi:10.1073/pnas.1119197109 (2012).
- 7 Kiecker, C. & Niehrs, C. A morphogen gradient of Wnt/beta-catenin signalling regulates anteroposterior neural patterning in *Xenopus*. *Development* **128**, 4189-4201 (2001).
- 8 Farin, H. F. *et al.* Visualization of a short-range Wnt gradient in the intestinal stem-cell niche. *Nature* **530**, 340-343, doi:10.1038/nature16937 (2016).
- 9 Alexandre, C., Baena-Lopez, A. & Vincent, J. P. Patterning and growth control by membrane-tethered Wingless. *Nature* **505**, 180-185, doi:10.1038/nature12879 (2014).
- 10 Tian, A., Duwadi, D., Benchabane, H. & Ahmed, Y. Essential long-range action of Wingless/Wnt in adult intestinal compartmentalization. *PLoS Genet* **15**, e1008111, doi:10.1371/journal.pgen.1008111 (2019).
- 11 Zecca, M., Basler, K. & Struhl, G. Direct and long-range action of a wingless morphogen gradient. *Cell* **87**, 833-844, doi:10.1016/s0092-8674(00)81991-1 (1996).
- 12 Harmansa, S., Hamaratoglu, F., Affolter, M. & Caussinus, E. Dpp spreading is required for medial but not for lateral wing disc growth. *Nature* **527**, 317-322, doi:10.1038/nature15712 (2015).
- 13 Yan, D., Wu, Y., Feng, Y., Lin, S. C. & Lin, X. The core protein of glypican Dally-like determines its biphasic activity in wingless morphogen signaling. *Dev Cell* **17**, 470-481, doi:10.1016/j.devcel.2009.09.001 (2009).
- 14 Franch-Marro, X. *et al.* Glypicans shunt the Wingless signal between local signalling and further transport. *Development* **132**, 659-666, doi:10.1242/dev.01639 (2005).
- 15 Stanganello, E. *et al.* Filopodia-based Wnt transport during vertebrate tissue patterning. *Nat Commun* **6**, 5846, doi:10.1038/ncomms6846 (2015).

315 16 Baeg, G. H., Selva, E. M., Goodman, R. M., Dasgupta, R. & Perrimon, N. The
316 Wingless morphogen gradient is established by the cooperative action of Frizzled and
317 Heparan Sulfate Proteoglycan receptors. *Dev Biol* **276**, 89-100,
318 doi:10.1016/j.ydbio.2004.08.023 (2004).

319 17 Reichsman, F., Smith, L. & Cumberledge, S. Glycosaminoglycans can modulate
320 extracellular localization of the wingless protein and promote signal transduction. *J*
321 *Cell Biol* **135**, 819-827, doi:10.1083/jcb.135.3.819 (1996).

322 18 Baena-Lopez, L. A., Franch-Marro, X. & Vincent, J. P. Wingless promotes
323 proliferative growth in a gradient-independent manner. *Sci Signal* **2**, ra60,
324 doi:10.1126/scisignal.2000360 (2009).

325 19 Tang, X. *et al.* Roles of N-glycosylation and lipidation in Wg secretion and signaling.
326 *Dev Biol* **364**, 32-41, doi:10.1016/j.ydbio.2012.01.009 (2012).

327 20 Kakugawa, S. *et al.* Notum deacylates Wnt proteins to suppress signalling activity.
328 *Nature* **519**, 187-192, doi:10.1038/nature14259 (2015).

329 21 Fuerer, C., Habib, S. J. & Nusse, R. A study on the interactions between heparan
330 sulfate proteoglycans and Wnt proteins. *Dev Dyn* **239**, 184-190,
331 doi:10.1002/dvdy.22067 (2010).

332 22 Mihara, E. *et al.* Active and water-soluble form of lipidated Wnt protein is maintained
333 by a serum glycoprotein afamin/alpha-albumin. *Elife* **5**, doi:10.7554/eLife.11621
334 (2016).

335 23 Kim, M. S., Saunders, A. M., Hamaoka, B. Y., Beachy, P. A. & Leahy, D. J. Structure
336 of the protein core of the glypican Dally-like and localization of a region important
337 for hedgehog signaling. *Proc Natl Acad Sci U S A* **108**, 13112-13117,
338 doi:10.1073/pnas.1109877108 (2011).

339 24 Pei, J. & Grishin, N. V. Cysteine-rich domains related to Frizzled receptors and
340 Hedgehog-interacting proteins. *Protein Sci* **21**, 1172-1184, doi:10.1002/pro.2105
341 (2012).

342 25 Hirai, H., Matoba, K., Mihara, E., Arimori, T. & Takagi, J. Crystal structure of a
343 mammalian Wnt-frizzled complex. *Nat Struct Mol Biol* **26**, 372-379,
344 doi:10.1038/s41594-019-0216-z (2019).

345 26 Awad, W. *et al.* Structural Aspects of N-Glycosylations and the C-terminal Region in
346 Human Glypican-1. *J Biol Chem* **290**, 22991-23008, doi:10.1074/jbc.M115.660878
347 (2015).

348 27 Sivasankaran, R., Calleja, M., Morata, G. & Basler, K. The Wingless target gene Dfz3
349 encodes a new member of the Drosophila Frizzled family. *Mech Dev* **91**, 427-431
350 (2000).

351 28 Schilling, S., Steiner, S., Zimmerli, D. & Basler, K. A regulatory receptor network
352 directs the range and output of the Wingless signal. *Development* **141**, 2483-2493,
353 doi:10.1242/dev.108662 (2014).

354 29 Mii, Y. & Taira, M. Secreted Frizzled-related proteins enhance the diffusion of Wnt
355 ligands and expand their signalling range. *Development* **136**, 4083-4088,
356 doi:10.1242/dev.032524 (2009).

357 30 Hayashi, Y., Kobayashi, S. & Nakato, H. Drosophila glypicans regulate the germline
358 stem cell niche. *J Cell Biol* **187**, 473-480, doi:10.1083/jcb.200904118 (2009).

359 31 Wang, X. & Page-McCaw, A. A matrix metalloproteinase mediates long-distance
360 attenuation of stem cell proliferation. *J Cell Biol* **206**, 923-936,
361 doi:10.1083/jcb.201403084 (2014).

362 32 Serralbo, O. & Marcelle, C. Migrating cells mediate long-range WNT signaling.
363 *Development* **141**, 2057-2063, doi:10.1242/dev.107656 (2014).

33 Gonzalez-Mendez, L., Gradilla, A. C. & Guerrero, I. The cytoneme connection: direct long-distance signal transfer during development. *Development* **146**, doi:10.1242/dev.174607 (2019).

AUTHOR INFORMATION

Reprints and permissions information is available at www.nature.com/reprints

Correspondence and requests for materials should be addressed to yvonne@strubi.ox.ac.uk or jp.vincent@crick.ac.uk

COMPETING INTERESTS

The authors declare no competing interest.

DATA AVAILABILITY STATEMENT

X-ray crystallographic coordinates and structure factor files generated during the current study are available from the RCSB Protein Data Bank (PDB), accession code 6XTZ. Full scans for all western blots are provided in Supplementary Fig. 1. Source Data behind Figs. 2 and 4 and Extended Data Figs. 1, 4-5 are available within the manuscript files.

METHODS are linked to the online version of the paper at www.nature.com/nature.

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

ACKNOWLEDGEMENTS

We thank Cyrille Alexandre for plasmids and advice, Joachim Kurth for *Drosophila* injections. Thomas Walter for technical support with crystallization, Weixian Lu and Yuguang Zhao for help with tissue culture and advice. We thank Karl Harlos and staff at Diamond Light Source beamlines (i03, i04 and i04-1) for assistance with x-ray data collection (proposal MX19946). This work was supported by core funding to the Francis Crick Institute to JPV (CRUK FC001204, MRC FC001204, and Wellcome Trust FC001204), the European Union (ERC grants WNTEXPORT (294523) to JPV, and CilDyn (647278) to CS), Cancer Research UK (C375/A17721 to EYJ, and C20724/A26752 to CS). LV is supported by Wellcome Trust PhD Training Programme 102164/B/13/Z. The Wellcome Centre for Human Genetics is supported by Wellcome Trust Centre grant 203141/Z/16/Z.

AUTHOR CONTRIBUTIONS

Experimental contributions were as follows: *Drosophila* developmental genetics and cell-based assays (IMcG), genetic analysis of LPPs (KB), biophysics and structural biology (LV, BB, TM, CS); peptide synthesis (DJ, NO'R). The project was conceived by IMcG, LV, EYJ, and JPV. The first draft of the paper was written by JPV, EYJ, IMcG, and LV. All the authors contributed to the design and interpretation of experiments.

FIGURE LEGENDS

Figure 1: Spread of Wingless does not involve multimeric assemblies but requires Dlp.

a) Morphotrap (NRT-MYC-LaG16) driven in the posterior compartment by *hh-Gal4* captures GFP-Wingless, but not Wingless-HA (both expressed from knock-in alleles). In the control anterior compartment, both forms of Wingless show a graded distribution. The experiment was repeated independently three times with similar results. **b, c)** Extracellular Wingless is reduced to a greater extent in clones lacking Dlp than clones lacking Dally (clones marked by the absence of GFP (white arrowheads). Scale bars represent 10µm in a and 25µm in b and c. The experiments were repeated independently three times with similar results.

Figure 2: A subset of glypicans bind palmitoleate. a) Dlp driven by *ptc-Gal4* (transversal to Wingless stripe) captures GFP-Wingless but not GFP-Wingless[S239A]. The experiments were repeated independently three times with similar results. Scale bars represent 50µm **b)** Representative reference-subtracted BLI traces of Dlp^{core} and Dally^{core} tested against biosensors loaded with palmitoleoylated peptides (sequence from human Wnt7a, chosen because of improved solubility relative to the Wingless sequence). Only the Dlp^{core}/palmitoleoylated peptide pair gave a signal. The experiments were repeated independently three times with similar results. **c)** Human GPC6 (Dlp family), but not human GPC5 (Dally family), expressed with *ptc-Gal4* captured GFP-Wingless at the cell surface. Scale bars represent 50µm. **d, e)** Members of the Dlp, but not Dally, family stabilise GFP-Wingless in solution. S2 cells, cultured in serum free medium, were co-transfected with GFP-Wingless and non-membrane tethered (ΔGPI) V5-tagged forms of the indicated glypicans, or a secreted form of Cherry (negative control). Media were collected and concentrated 20-fold and the amount of Wingless in solution was determined by Western blot. Note that these proteins could be sulfated, which may contribute to their solubilizing activity. Dlp family

members run at lower sizes than predicted, perhaps because of processing by furin. The experiments were repeated independently three times with similar results.

Figure 3: Structural basis of glypican-Wnt peptide interaction. **a)** Superposition between Dlp^{core} apo structure (PDB ID: 3odn, pale yellow) and Dlp^{core} in complex with human Wnt7a palmitoleoylated peptide (marine). The palmitoleoylated serine (PMS) from Wnt7a peptide is depicted in spheres in atomic colouring (C: orange, N: blue, O: red). N- and C-termini are indicated. The black arrow indicates domain movement of the C lobe between apo and palmitoleoylated Wnt7 peptide-bound form. **b)** Close-up view of the Dlp C-lobe, revealing the conformational rearrangement of helices $\alpha 9$ and $\alpha 10$ opening the Wnt binding pocket. Dlp-M175 and -N367 mutated to cysteines to form a disulphide bridge to interfere with Wnt binding are indicated by red spheres. **c)** Close-up view of the lipid-binding pocket. Stick representation of residues lining the binding pocket (located within a 4.5 Å range from the Wnt peptide lipid for hydrophobic interactions). The red sphere indicates the site of one of the mutations predicted to interfere with Wnt binding (S168M). The positions of the F172T/F195Y mutations are also labelled. The Fo-Fc omit electron density map for the Wnt peptide palmitoleate is shown in purple chicken wire presentation, contoured at 2.5 σ .

Figure 4: Structure-guided point mutants impair Dlp lipid interaction. **a)** Representative FSEC profiles of purified Dlp^{core} wild-type (blue), S168M (yellow), M175C/N367C (purple) mutants incubated with bodipy-labelled palmitic acid (C16:0), showing a reduction of fluorescence emission of mutants with respect to wild-type. This is suggestive of diminished binding affinity. The fluorophore profile in absence of proteins (green) is presented as control. 280 nm protein absorbance confirms protein presence, similar elution of wildtype and mutant proteins (ruling out mis-folding artefacts) and co-elution with the fluorescent

457 peak. The experiments were repeated independently three times with similar results. **b)** Dlp-
458 HA, Dlp[S168M]-HA and Dlp[M175C/N367C]-HA were overexpressed with *ptc-gal4* and
459 wing discs stained for extracellular Wingless. Scale bars represent 50µm. The experiments
460 were repeated independently three times with similar results. **c)** Dlp[S168M]^{ΔGPI} less
461 efficiently stabilises GFP-Wingless in solution than Dlp^{ΔGPI}, while Dlp[M175C/N367C]^{ΔGPI}
462 has virtually no solubilisation activity. S2 cells, cultured in serum free medium, were co-
463 transfected with GFP-Wingless and either V5-tagged Dlp[S168M]^{ΔGPI},
464 Dlp[M175C/N367C]^{ΔGPI}, Dlp^{ΔGPI}, or a secreted Cherry. Medium was collected and
465 concentrated 20-fold and the amount of wingless in solution determined via Western blot.
466 The experiments were repeated independently three times with similar results.

467
468

EXTENDED DATA FIGURE LEGENDS

Extended Data Figure 1: Extracellular wingless, captured by morphotrap, colocalizes

with Dlp^{ΔGPI} but not exosomes or lipophorin particles. **a)** A membrane tethered anti-GFP nanobody (Vhh4-CD8-HA, morphotrap), expressed in a transversal stripe with *dpp-Gal4*, leads to accumulation of GFP-Wingless (from a knock-in allele³⁴) where the two expression domains overlap. The apparent gap in morphotrap expression is due to the known low activity of *dpp-gal4* there. Residual expression is nevertheless sufficient to trap GFP-Wingless. **b-d)** Immunofluorescent localization of morphotrap-enriched GFP-Wingless and endogenous ApoL or endogenous Hrs. **d)** Immunofluorescent localization of morphotrap-enriched GFP-Wingless and overexpressed Dlp^{ΔGPI}-V5. Here, morphotrap is expressed with *dpp-LexA* and Dlp^{ΔGPI}-V5 with *wg-Gal4*. White colour indicates extensive colocalisation. Dlp^{ΔGPI}-V5 expression was limited to 24 hrs with Gal80^{ts} to avoid pleiotropic effects. **e)** Colocalisation was quantified where the morphotrap and GFP-Wingless expression domains intersect. Error bars show standard deviation from the mean, n=4 (Dlp^{ΔGPI}-V5), n=13 (ApoL) and n=10 (Hrs), where n=number of wing discs. Scale bars represent 50μm in a and 10μm in b-d. All experiments were repeated independently three times with similar results.

Extended Data Figure 2: Genetic perturbation of exosomes or lipophorin particles does

not alter the distribution of extracellular Wingless. **a)** Expression of dominant negative Vps4 with *hh-Gal4* in the posterior compartment (limited to 8 hrs with Gal80^{ts} to avoid pleiotropic effects of sustained VPS4 inhibition) does not affect extracellular Wingless despite disruption of MVB formation indicated by accumulation of ubiquitin. Anterior compartment serves as a control. Dashed line denotes anterior posterior boundary. **b)** Expression of extracellular Wingless is largely unaffected by the loss of Hrs activity. The

posterior compartment was rendered homozygous for a null *hrs* mutation using the indicated genotype. **c-d)** Overexpression of the lipophorin receptor Lpr2E-HA for 24hrs with the *hh-Gal4* driver increases the uptake of ApoL in the posterior compartment but has no effect on extracellular Wingless. The anterior compartment serves as a control. **e)** Extracellular Wingless and ApoL in wing discs from *w118* (control) or homozygotes for a deficiency that removes the two main lipophorin receptors Lpr1/2. Lipophorin uptake is reduced in the deficiency line but neither total or extracellular Wingless is altered. Scale bars represent 50µm. All experiments were repeated independently three times with similar results.

Extended Data Figure 3: Genetic perturbation of Dlp and dally but not of SWIM alters the distribution of extracellular Wingless.

a) Expression of an RNAi against *SWIM* in the posterior compartment (*en-Gal4*) does not alter extracellular or total Wingless. Scale bar represents 50µm. **b)** Schematic representation of the *SWIM* locus and the CRISPR-Cas9 strategy used to delete the gene. Successful deletion was verified by PCR using two independent primer pairs indicated by purple and red arrowheads. **c)** Extracellular Wingless and Distal-less expression in control (*w1118*) and *Swim*^{KO} wing discs. Neither is altered upon *SWIM* deletion. Scale bars represent 50µm. **d)** Extracellular Wingless is reduced in clones lacking both Dlp and Dally (marked by the absence of GFP (white arrowheads). Scale bars represent 25µm. All experiments were repeated independently three times with similar results.

Extended data Figure 4: Further evidence for the lipid binding activity of Dlp class glypicans. **a)** GFP-Wingless[S239A] expressed from a knock-in allele is trapped by CD8-VHH expressed with *dpp-Gal4*. This result shows that GFP-Wingless[S239A] is secreted and can be captured in the extracellular space and thus serves as a positive control for Fig. 2a.

Scale bars represent 50µm. **b)** Dlp^{core} and Notum[S237A], but not Dally^{core}, preferentially bind a palmitoleoylated peptide (sequence from the Wingless protein). Biotinylated palmitoleoylated and non-palmitoleoylated peptides were incubated with medium from S2 cells expressing Dlp^{core}-V5, Notum[S237A]-V5 or Dally^{core}-V5. Biotinylated peptides were pulled down with streptavidin beads and the extent to which Dlp^{core}, Notum[S237A]-V5 and Dally^{core} are co-pulled down was determined by western blot. A peptide-based approach was used because of difficulties associated with the production of soluble Wingless protein. Binding was estimated from the amount of protein co-pulled down from conditioned medium by streptavidin beads. **c)** Steady-state analysis of the Dlp^{core} vs. palmitoleoylated hWnt7a peptide interaction measured by BLI shown in Fig. 2b. K_d is calculated from a global fit of three independent experiments. Due to the effect of non-specific binding on the shape of the binding isotherm curves (which could not be alleviated by detergents in light of the lipid-based nature of the interaction) we could not perfectly fit a 1:1 Langmuir model, therefore the indicated apparent dissociation constant is an estimate, not an exact value. **d)** Representative reference-subtracted BLI traces of Dlp^{core} against biosensors loaded with non-palmitoleoylated peptide (sequence from relevant region of human Wnt7a). No significant binding could be detected (compare to Fig. 2b). The experiments were repeated independently three times with similar results. **e)** Human GPC4 (Dlp family), but not human GPC3 (Dally family), expressed with *ptc-Gal4* captured GFP-Wingless at the cell surface. This panel extends the data of Fig. 2c. Scale bars represent 50µm. All experiments were repeated independently three times with similar results.

Extended data Figure 5: Effects of Dlp class glypicans on Wingless signalling. a) GPC4 and GPC6, but not GPC3 and GPC5, driven with *ptc-Gal4* inhibit the high target gene *senseless*. Scale bars represent 50µm. **b)** GPC4 and GPC6, but not GPC3 and GPC5,

expressed with *en-Gal4* extend the range of the low target gene *Distal-less* in the posterior compartment. Scale bars represent 50µm. **b')** *Distal-less* immunoreactivity was quantified in the indicated boxed regions and plotted separately for the anterior and posterior, where the glypicans were overexpressed. **c)** Dlp conditioned medium stabilises GFP-Wingless in solution. Conditioned medium from S2 cells or S2 cells expressing Dlp^{ΔGPI}-V5 was added to S2 cells expressing GFP-Wingless. 12hrs later the medium was collected, concentrated 20-fold and the amount of GFP-Wingless in solution was determined via Western blot. **d)** Wingless solubilized by Dlp^{ΔGPI} is signalling competent. Medium from cells that were mock-transfected, transfected with GFP-Wingless alone, or co-transfected with either V5 tagged Dally^{ΔGPI} or Dlp^{ΔGPI} was collected, concentrated and added to S2R+ cells expressing a luciferase reporter of Wingless signaling. Error bars show standard deviation from the mean. n=4, n=independent experiments and each independent experiment was performed in triplicate. Asterisk denotes statistical significance, as assessed by an unpaired (two tailed) t-test (p=0.0011). ns denotes no statistical significance (p=0.128). All experiments were repeated independently three times with similar results.

Extended Data Figure 6. Steric clashes prevent Wnt lipid binding to glypican CRD.

Comparison of the conserved CRD architecture of: **a, b)** *Drosophila* Dlp^{core} structure in complex with Wnt palmitoleoylated serine from Wnt peptide. We could confirm that the Dlp^{CRD} contains the full set of canonical disulphide-bonds. **c)** apo *Drosophila* Dlp^{core} (PDB ID: 3odn); **d)** human GPC1 (PDB ID: 4ywt); **e)** mouse Frizzled 8 in complex with palmitoleic moiety from *Xenopus* Wnt8 (PDB ID: 4f0a); **f)** mouse Frizzled 8 in complex with palmitoleic moiety from human Wnt3 (PDB ID: 6ahy). Evolutionary conserved disulphides are shown in black and numbered. **g,h)** Superposition of Dlp^{core} CRD and mouse Frizzled 8

CRD bound to lipidated Wnt8 (**g**) and Wnt3 (**h**), showing that a conserved helix of glypican CRD sterically hinders binding of the Wnt palmitoleate.

Extended Data Figure 7. Additional structural information on Dlp^{core} in complex with hWnt7a peptide. **a)** Sequence of Dlp^{core} construct from the complexed structure annotated with secondary structure elements. To facilitate comparison between the complexed and apo structure, secondary structure nomenclature of the complex reflects that of the previously published apo structure (PDB ID: 3odn). α indicates alpha-helices, η indicates 3_{10} -helices. **b)** Side and front view of the lipid binding cavity of Dlp^{core} in complex with the Wnt palmitoleoylated peptide, showing the cavity extension beyond the end of the Wnt peptide acyl chain. This additional space likely accommodates the bodipy moiety of bodipy-palmitate for the assays presented in Fig. 4a. The internal volume of the cavity is coloured in blue, with the palmitoleoylated serine from the Wnt peptide represented as spheres in atomic colouring (C: orange, N: blue, O: red).

Extended Data Figure 8. Several types of omit maps show and support the modelling of the electron density in the binding pocket as palmitoleoylated serine (PMS) from the palmitoleoylated Wnt peptide. **a)** Coot-displayed Fo-Fc omit map (left) generated from the refined model after removal of PMS, as shown in Figure 3c. To help orientation and comparison, panel c from Figure 3 is duplicated here, displaying the same map in Pymol (right). The maps are contoured at the same level in the two programmes ($\pm 2.5 \sigma$). **b)** Coot-displayed Fo-Fc omit map (contoured at $\pm 2.5 \sigma$) generated from the refined model, after removal of PMS, application of simulated annealing and one round of coordinate and B-factor refinement. **c)** Coot-displayed Fo-Fc map (left) and 2Fo-Fc map (right) of the last refinement iteration before modelling PMS in the electron density. As PMS was never

modelled, these maps are unbiased. The Fo-Fc map and 2Fo-Fc map are contoured at $\pm 2.5 \sigma$ and 1σ , respectively. **d)** Polder map generated from the refined model using phenix.polder³⁵. This omit map, whose characteristic is to enhance weak electron density features in the omit region, shows additional electron density that can be assigned to the peptide portion of the palmitoleoylated peptide, therefore further supporting PMS modelling into the electron density. The map is contoured at $\pm 2.5 \sigma$.

Extended Data Figure 9. In vivo characterization of Dlp/Dally chimeras.

a) Multiple sequence alignment of residues forming binding pocket of human and *Drosophila melanogaster* glypicans. Sequences are coloured according to Clustal X colouring scheme (blue = hydrophobics; green = polar). **b)** Extracellular distribution upon overexpression of Dlp-HA, Dlp[F172T,F195Y]-HA, Dlp[R169E,T170N,Q171M,F172T]-HA or Dally[E149R,N150T,M151Q,T152F]-HA with *ptc-gal4*. Scale bars represent 50 μ m. **c)** Model illustrating how Dlp acts both as a reservoir of signalling competent Wnt and as a co-receptor. The weight of these activities depends on the relative abundance of Dlp to Frizzled and on the relative affinities of Dlp and Frizzled for Wnt. Configuration of glypican core and HS chains are inspired from the structure of hGPC1²⁶. All molecules drawn approximately to scale. The HS chains are presented as orange circles, the glypican stalk regions from which they originate as black lines, and the GPI anchors as orange triangles.

EXTENDED DATA TABLE LEGEND

Extended Data Table 1. Data collection and refinement statistics (molecular replacement).

EXTENDED DATA TABLE FOOTNOTES

* Values in parentheses are for highest-resolution shell.
The diffraction dataset was collected from a single crystal.

623
624
625

METHODS

Immunostaining and microscopy

The following primary antibodies were used: guinea-pig anti-Senseless (1:1000, gift from H. Bellen), rabbit anti-V5 (1:500, Cell Signalling), mouse anti-V5 (1:500, Invitrogen), rabbit anti-GFP (1:500, Abcam), mouse anti-Wingless (1:200, Hybridoma bank), anti-Hrs (1:250, DSHB), anti-ApoL (1:1000, gift from S. Eaton), rat anti-HA (1:250, Roche, 3F10), anti-Ubiquitin (1:1000, EMD Millipore), guinea-pig anti-Distal-less (1:1000, gift from Richard S. Mann). Secondary antibodies used were Alexa 488, Alexa 555 and Alexa647 (1:500, Molecular Probes). Total and extracellular immunostaining of imaginal discs was performed as previously described. Imaginal discs were mounted in Vectashield with DAPI (Vector Laboratories) and imaged using a Leica SP5 confocal microscope. Confocal images were processed with ImageJ (N.I.H) and Photoshop CS5.1 (Adobe). Images were analysed using ImageJ to determine Mander's overlap coefficient and Pearson's correlation coefficient. Colocalization was measured where the morphotrap expression domain and the domain of GFP-Wingless overlap. Images were manually thresholded to remove background signal.

***Drosophila* husbandry and clone induction**

All crosses were performed at 25°C except those to generate discs shown in Extended Data Fig. 1d and Extended Data Fig. 2a, 2c and 2d, where larvae were reared at 18°C, the Gal80^{ts} permissive temperature, and then shifted to 29°C, the restrictive temperature for the indicated time (see figure legends).

***Drosophila* genotypes**

652 All lines are available upon request. Detailed Drosophila genotypes are listed
653 Supplementary Table 1.

654

655 **Expression vectors for cultured Drosophila cells**

656 Drosophila S2 or S2R+, obtained from the Drosophila Genomics Resource Centre (DGRC),
657 were cultured at 25°C in Schneider's medium + L-glutamine (Sigma) containing 10% (v/v)
658 fetal bovine serum (FBS; Life Technologies) and 0.1 mg/mL Pen/Strep (Life Technologies).
659 Cell lines were not authenticated, but were tested for, and free from, mycoplasma. To
660 generate plasmids expressing V5-tagged forms of Dlp^{ΔGPI} and Dlp^{core}, amino acids 53-723
661 and 53-622 of Dlp was amplified from pOT2-Dlp (DGRC gold collection) adding a V5 tag
662 (GKPIPPLLGLDST) at the C-terminus and a BIP-signal peptide at the N-terminus and
663 inserted into pMT-V5-HisA (ThermoFisher). For Dlp[S168M]^{ΔGPI}-V5 a gene fragment
664 encoding a region around the point mutation was generated (Integrated DNA Technologies)
665 and subcloned into pMT-Dlp^{ΔGPI}-V5. To generate plasmids expressing V5-tagged Dally^{ΔGPI}
666 and Dally^{core}, amino acids 1-600 and 1-546 of Dally were amplified from pUAST-secDally-
667 Myc (DNA from Nakato H.) adding a V5 tag (GKPIPPLLGLDST) at the C-terminus.
668 SecCherry was generated by adding BIP-signal peptide at the N-terminus and inserting it into
669 pMT-V5-HisA. To generate V5-tagged Notum[S237A], Notum[S237A] cDNA was
670 amplified, adding a V5 tag (GKPIPPLLGLDST) at the C terminus and cloned into pMT-
671 V5-HisA. To generate pMT-GFP-Wg, GFP-IgG2 linker was placed after the signal peptide
672 of Wingless. To generate GPC3^{ΔGPI}-V5 amino acids 1-535 were amplified from a GPC3
673 (NM_004484) human cDNA clone (Origene) adding a V5 tag at the C-terminus. To generate
674 GPC4^{ΔGPI}-V5 amino acids 1-487 were amplified from a GPC4 (NM_001448) human cDNA
675 clone (Origene) adding a V5 tag at the C-terminus. To generate GPC5^{ΔGPI}-V5 amino acids 1-
676 528 were amplified from a GPC5 (NM_004466) human cDNA clone (Origene) adding a V5

tag at the C-terminus. To generate GPC6^{ΔGPI}-V5 amino acids 1-529 were amplified from a GPC6 (NM_005708.3) human cDNA clone (Sino Biological Inc.) adding a V5 tag at the C-terminus.

Generation of transgenic flies

The Swim^{KO} line was generated by deleting all three coding exons depicted in Extended Data Fig 2e. The regions were replaced with a PAX-Cherry selection cassette, which was used to identify potential candidates, subsequently confirmed by PCR. The KO line is homozygous viable and fertile with no apparent morphological phenotype. Two variants of morphotrap were generated. The nanobody Vhh4, preceded by a BIP signal peptide, was cloned in frame with the transmembrane region of CD8 and an intracellular HA-tag and inserted into the pUAST vector, lines on the second and third chromosome were subsequently generated by random integration. The nanobody LaG16 was cloned in frame with the type II transmembrane protein NRT with a Myc-tag as a spacer to generate NRT-Myc-LaG16, which was cloned into pUAS-attB and inserted into the attP2 landing site. GFP-Wingless[S239A] was generated by inserting full-length *GFP-wg[S239A]* cDNA along with 135 bp of 5' untranslated region (UTR) and 1,200 bp of 3' UTR into RIV{mini-white} and reintegrating it into the *wg*^{KO} line⁹. The GFP was placed after the signal peptide and an IgG2 linker was inserted after the GFP. UAS-attB vectors encoding GPC3, GPC4, GPC5 and GPC6 were generated by amplifying coding regions from cDNA clones (see expression vectors for cultured *Drosophila* cells for more info on cDNA clones) and adding a V5 tag immediately after the signal peptides. The resulting UAS-attB vectors were inserted into the attP2 landing site. UAS-Dlp^{ΔGPI}-V5 was generated by sub-cloning Dlp^{ΔGPI}-V5 from pMT-Dlp^{ΔGPI}-V5 into the UAS-attB vector and inserting it into the attP2 landing site. UAS-Dlp[S168M] was generated by sub-cloning a region encoding Dlp[S168M] from pMT-Dlp[S168M]^{ΔGPI}-V5

into UAS-Dlp-HA (from Stephen Cohen) and inserting it into the attP2 landing site. UAS-Dlp[M175C/N367C]-HA, UAS-Dlp[F172T/F195Y]-HA and UAS-Dlp[R169E/T170N/Q171M/F172T]-HA were generated by sub-cloning gene fragments (synthesized by Integrated DNA technologies) altered to encode the relevant mutations into UAS-Dlp-HA. UAS-Dally[E149R/N150T/M151Q/T152F]-HA was generated by sub-cloning a gene fragment (synthesized by Integrated DNA technologies) altered to encode the relevant mutations into pAct-Dally-HA and subsequently sub-cloning into UAS-attB. All Dlp and Dally transgenes were inserted into the attP2 landing site. Transgenic lines were generated in house or with BestGene Inc.

Immunoblotting and Immunoprecipitation

Cell lysates were produced using Triton Extraction Buffer (TEB): 50 mM Tris pH7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton-X100. Cells were incubated in TEB for 10 min on ice then spun at 14,000 rpm for 10 min at 4°C to remove remaining cell debris. Samples were run on 4-12% Bis-Tris NuPAGE gels (Invitrogen) with MES buffer. Proteins on gel were transferred onto nitrocellulose membrane using Biorad gel transfer System (Invitrogen). The membranes were washed with dH₂O and blocked with 5% skimmed milk in 0.1% tween-20 PBS (PBS-T) for 30 min at room temperature. Membranes were incubated with primary antibodies (mouse monoclonal anti-V5 (Life Technologies, 1:5000), rabbit anti-GFP (Abcam, 1:5000), anti-Beta-Tubulin (DSHB, 1:2000) and anti-Cherry (Abcam, 1:3000)) diluted in 5% milk PBS-T overnight at 4°C and washed with PBS-T 3 times before incubation with 680RD or 800CW conjugated secondary antibodies (anti-mouse or anti-rabbit; LI-COR, 1:7000). Membranes were washed again in PBS-T and 0.02% SDS, developed using an Odyssey Clx western blotting detection system (LI-COR). Uncropped Western blot images can be found in Supplementary Fig. 1.

727

728 For peptide immunoprecipitations S2 cells were transiently transfected with either Dlp^{core}-V5,
729 Dally^{core}-V5 or Notum[S237A]-V5. 72 hours later medium was collected and spun at
730 14,000 rpm for 10 min at 4°C to remove cell debris. Biotinylated palmitoleoylated and
731 biotinylated non-palmitoleoylated Wingless peptides resuspended in 10 mM Tris-HCl, pH 8,
732 35 mM NaCl and 10% DMSO were added to the cleared medium at a final concentration of
733 10µM and incubated for 8 hours at 4 degrees. Neutravidin beads were added and incubated
734 overnight at 4 degrees. Beads were then washed in wash buffer (10 mM Tris-HCl, pH 8, 35
735 mM NaCl) four times and protein was subsequently eluted from the beads by boiling in LDS
736 sample buffer for 5mins.

737

738 **Topflash signalling assay**

739 S2R+ cells were plated in 60cm dish and transfected with 1µg of a plasmid containing a
740 Wingless-responsive promoter driving Firefly luciferase and a ubiquitous Copia promoter
741 driving Renilla luciferase (made by Cyrille Alexandre). After 48 hours the S2R+ cells were
742 counted and 1×10⁶ cells were plated in each well of a 12 well plate and allowed to attach.
743 After 6 hours the medium was removed and replaced with concentrated conditioned medium
744 (20×). After 24 hours of treatment, the cells were lysed using cold passive lysis buffer
745 (Promega), Firefly and Renilla luciferase levels were measured using the Dual Luciferase
746 Reporter Assay System (Promega) and the Firefly/Renilla ratio calculated to give the
747 Wingless signalling activity. Each condition was tested in triplicate and the experiment was
748 repeated four times.

749

750 **Large scale expression and purification of Dlp^{core} wild-type and Dally^{core}**

751 The cDNA coding for *Drosophila melanogaster* Dlp^{core} (residues D74-Q617, UNIPROT ID:
 752 Q9VUG1; note that this is slightly different from the Dlp^{core} described above, P52-Y622) was
 753 cloned into pHR-STRUBI-3c-Twin-Strep-IRES-EmGDP: the plasmid encodes the protein of
 754 interest adding a Human Rhinovirus (HRV) 3C Protease-cleavable Twin-Strep tag at the C-
 755 terminus, and allows both transient expression and lentiviral-based transduction of target
 756 cells³⁶.

757 Dlp contains one canonical and one cryptic furin cleavage site at position 397 and 437,
 758 respectively. To produce homogenous batches of protein and to account for potential effects
 759 of furin processing on lipid binding, two protein forms were generated, one wild-type form
 760 containing the native furin cleavage site and one form where both furin sites were destroyed
 761 (K398Q, K399A, R402Q, R438Q, R441A). No difference in lipid binding behaviour was
 762 observed between these two forms. For crystallisation purposes, the furin mutant form was
 763 used.

764 The protein was expressed – secreted in the culture medium - either by transient transfection
 765 of HEK293S GnTI(-) cells or by lentiviral transduction of HEK293S GnTI(-) TetR cells³⁷
 766 (which allow doxycycline-controlled inducible expression) according to published
 767 protocols^{36,38}. In the latter case, expression was induced using 1 ug/mL of doxycycline for 96
 768 hours at 37 °C. For transient transfection, conditioned media was collected seven days post-
 769 transfection.

770 In both cases, harvested conditioned media was dialyzed against 50 mM Tris-HCl, pH 8, 200
 771 mM NaCl using using a QuixStandTM benchtop system (GE Healthcare) connected to a 60
 772 cm Xampler Cartridge (GE Healthcare) with a 10 kDa nominal MWCO. Initial purification
 773 was performed by Strep-tagTM affinity chromatography (StreptactinXT High Capacity
 774 column, IBA Lifesciences). Briefly, the protein was loaded overnight with continuous
 775 circulation on the column, before being eluted in 100 mM Tris-HCl, pH 8, 150 mM NaCl, 1

mM EDTA, 50 mM biotin. The protein was further purified by size-exclusion chromatography (SEC) (Superdex 200 Increase 10_300 GL column, GE Healthcare) in a final buffer containing 10 mM Tris-HCl, pH 8, 35 mM NaCl. Between the affinity chromatography and SEC steps, the Twin-Strep-tag was removed by incubation for 48 hours at 4 °C with HRV 3C Protease, added at a 1:50 (w/w) protease:protein ratio.

Drosophila melanogaster Dally^{core} (residues 65-541, Uniprot ID: Q24114), fused C-terminally with a hexa-histidine (6xHis) tag, was cloned into the pHLsec vector and expressed by transient transfection in HEK293T cells in the presence of the class I α -mannosidase inhibitor, kifunensine^{38,39}. Conditioned media was collected five days post-transfection. Media was concentrated and diafiltrated as before into 25 mM phosphate pH 8, 250 mM NaCl. The protein was incubated with TALON® beads for 1 hour at 16°C. Beads were washed with 25 mM Phosphate pH 8, 250 mM NaCl, followed by washes in wash buffer containing 5 mM imidazole. The protein was eluted in wash buffer containing 250 mM imidazole. Samples were subjected to SEC using a Superdex 200 16/60 column (GE Healthcare) equilibrated in 10 mM HEPES pH 7.5, 150 mM NaCl.

Man(5)GlcNAc(2) and Man(5–9)GlcNAc(2) residual glycosylation produced by expression in GnTI(-) HEK293S or by HEK293T cells with kifunensine, respectively, was preserved for biophysical and HPLC analysis of protein-lipid interaction, while the samples for crystallisation were further deglycosylated by *in situ* deglycosylation by endo- β -N-acetylglucosaminidase F1 treatment³⁹.

Peptide synthesis

Abbreviations

DCM (dichloromethane); DIPEA (*N,N*-diisopropylethylamine); DMAP (dimethylaminopyridine); DMF (dimethylformamide); HATU (1-

801 [bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid
802 hexafluorophosphate); MeCN (acetonitrile); MeOH (methanol); MMT (monomethoxytrityl);
803 RT (room temperature); TFA (trifluoroacetic acid); TIS (triisopropylsilane);

804 *General Information*

805 All reagents were purchased from commercial sources (VWR, Fisher Scientific, ,
806 Novabiochem, Fluorochem) and used without further purification.

807

808 • *Synthesis of dmWg S239 ox Bio* (CH₃CO- KC(S-)*H*GMSGSC(S-)*T*VLK-(EDA)-Bio)
809 and dmWg S239 (C16:1) ox Bio (CH₃CO- KC(S-)*H*GMS(-C=O-
810 (CH₂)₇CH=CH(CH₂)₅CH₃)GSC(S-)*T*VLK-(EDA)-Bio)

811 Solid phase synthesis took place on an Activotec P-11 peptide synthesizer (Activotec) using a
812 Fmoc-Biotin NovaTag TM resin (0.2 mmol; Merck) and N(α)-Fmoc amino acids, including
813 Fmoc-Ser-OH (Merck). Fmoc-Ser-OH was incorporated at the palmitoleoylation site. HATU
814 was used as the coupling reagent with 5- fold excess of amino acids. Acetylation of the N
815 terminal of the peptide took place on the synthesizer by activation of acetic acid. Following
816 chain assembly, the peptidyl resin was split into two portions of approximately one third and
817 two thirds.

818

819 For dmWg S239 ox Bio the peptide was cleaved from the resin and protecting groups
820 removed by addition of a cleavage solution (95% TFA, 2.5% H₂O, 2.5% TIS). After 2 h, the
821 resin was removed by filtration and peptides were precipitated with diethyl ether on ice. The
822 peptide was isolated by centrifugation, then dissolved in H₂O and freeze dried overnight.
823 Next, disulphide bridge formation was as follows. Clear-OxTM (Peptides International) resin
824 (3 eq, 0.109 mmol, 330 mg of 0.33 mmol/g) was conditioned by swelling in DCM for 40
825 min, then washed with DMF, MeOH and water. The peptide (0.036 mmol, 60 mg) was

dissolved in 10 mL of deionised water, added to the resin, then reacted at RT with gentle agitation for 2 days. Following filtration to remove the resin and freeze drying, portions of the peptide were purified on a C8 reverse phase HPLC column (Agilent PrepHT Zorbax 300SB-C8, 21.2x250 mm, 7 m) using a linear solvent gradient of 10-50% MeCN (0.08% TFA) in H₂O (0.08% TFA) over 40 min at a flow rate of 8 mL/min. The peak fraction was analyzed by LC-MS on an Agilent 1100 LC-MSD. The calculated molecular weight of the peptide was in agreement with the mass found. Calculated MW: 1657.65, actual mass: 1657.65.

For dmWg S239 (C16:1) ox Bio the peptidyl resin was palmitoleoylated as follows. Palmitoleoyl chloride (20 eq, 3 mmol, 903 uL) was added to DMF (6 mL) and the solution added to the peptidyl resin (0.15 mmol). DMAP (0.1 eq, 2 mg) was dissolved in 2.25 mL pyridine and added to resin. Following reaction at RT, 16 h, gentle agitation, the peptidyl resin was washed with 3xDMF and 2 x DCM. The palmitoleoylated peptide was cleaved from the resin and protecting groups removed by addition of a cleavage solution (95% TFA, 2.5% H₂O, 2.5% TIS). After 1 h, the resin was removed by filtration and peptides were precipitated with diethyl ether on ice. The peptide was isolated by centrifugation, then dissolved in H₂O and freeze dried overnight. Next, disulphide bridge formation was as follows. Clear-OxTM (Peptides International) resin (3 eq, 0.127 mmol, 384 mg of 0.33 mmol/g) was conditioned by swelling in DCM for 40 min, then washed with DMF, MeOH and water. The peptide (0.042 mmol, 80 mg) was dissolved in 10 mL of deionised water, added to the resin, then reacted at RT with gentle agitation for 3 days. Following filtration to remove the resin and freeze drying, portions of the peptide were purified on a C8 reverse phase HPLC column (Agilent PrepHT Zorbax 300SB-C8, 21.2x250 mm, 7 m) using a linear solvent gradient of 5-100% MeCN (0.08% TFA) in H₂O (0.08% TFA) over 40 min at a flow

rate of 8 mL/min. The peak fraction was analyzed by LC–MS on an Agilent 1100 LC-MSD. The calculated molecular weight of the peptide was in agreement with the mass found. Calculated MW: 1894.33, actual mass: 1894.27.

- mmWNT7A 204-213 S206 C16:1 ox Bio

NH₂-K(Cys-S-) HGV(Ser-palmitoleoyl)GS(Cys-S-)TTKT-PEG-Bio

Solid phase synthesis took place on an Activotec P-11 peptide synthesizer (Activotec) using a Fmoc-PEG-Biotin NovaTagTM resin (0.2 mmol; Merck) and N(α)-Fmoc amino acids, including Fmoc-Ser-OH (Merck) and Boc-Lys(Boc)-OH (Fluorochem). Fmoc-Ser-OH was incorporated at the palmitoleoylation site and Boc-Lys(Boc)-OH was incorporated at the N terminal. HATU was used as the coupling reagent with 5- fold excess of amino acids. the peptidyl resin was palmitoleoylated as follows. Palmitoleoyl chloride (20 eq, 1.5 mmol, 452 uL) was added to DMF (6 mL) and the solution added to the peptidyl resin (0.075 mmol). DMAP (0.1 eq, 1 mg) was dissolved in 2.25 mL pyridine and added to resin. Following reaction at RT, 16 h, gentle agitation, the peptidyl resin was washed with 3xDMF and 2 x DCM. The palmitoleoylated peptide was cleaved from the resin and protecting groups removed by addition of a cleavage solution (95% TFA, 2.5% H₂O, 2.5% TIS). After 1 h, the resin was removed by filtration and peptides were precipitated with diethyl ether on ice. The peptide was isolated by centrifugation, then dissolved in H₂O and freeze dried overnight. Next, disulphide bridge formation was as follows. Clear-OxTM (Peptides International) resin (3 eq, 0.147 mmol, 700 mg Of 0.21 mmol/g) was conditioned by swelling in DCM for 40 min, then washed with DMF, MeOH and water. The peptide (0.049 mmol, 96 mg) was dissolved in 10 mL of deionised water, added to the resin, then reacted at RT with gentle agitation for 3 days. Following filtration to remove the resin and freeze drying, portions of the peptide were purified on a C8 reverse phase HPLC column (Agilent PrepHT Zorbax

300SB-C8, 21.2x250 mm, 7 m) using a linear solvent gradient of 10-75% MeCN (0.08% TFA) in H₂O (0.08% TFA) over 40 min at a flow rate of 8 mL/min. The peak fraction was analyzed by LC-MS on an Agilent 1100 LC-MSD. The calculated molecular weight of the peptide was in agreement with the mass found. Calculated MW: 1971.39, actual mass: 1969.90.

• mmWNT7A 201-213 S206 ox C16:1

NH₂-K(Cys-S-)HGV(Ser-16:1) GS(Cys-S-)TTKT-COOH

Solid phase synthesis took place on an Activotec P-11 peptide synthesizer (Activotec) using a Fmoc-Thr(tBu)-Wang resin LL (0.2 mmol; Merck) and N(α)-Fmoc amino acids, including Fmoc-Ser-OH, Fmoc-Cys(MMT)-OH, Fmoc-Gly-Ser(psiMe,Mepro)-OH (all Merck) and Boc-Lys(Boc)-OH (Fluorochem). Fmoc-Ser-OH was incorporated at the palmitoleoylation site and Boc-Lys(Boc)-OH was incorporated at the N terminal. HATU was used as the coupling reagent with 5-fold excess of amino acids. Palmitoleoyl chloride (18.5 eq, 3.7 mmol, 1000 μ L) was added to DMF (4 mL) and the solution added to the peptidyl resin (0.075 mmol). DMAP (0.1 eq, 2.5 mg) was dissolved in 2.50 mL pyridine and added to resin. Following reaction at RT, 16 h, gentle agitation, the peptidyl resin was washed with 3 x DMF and 2 x DCM. Next disulphide bridge formation on the resin was performed as follows. Methoxytrityl was removed from the two cysteine residues by treatment of the peptidyl resin for 2 min with 10 mL of 1% TFA, 5% TIS, rest DCM, then washed with DCM. This was repeated 7 times more. Next the peptidyl resin was treated with N-chlorosuccinimide (1 eq) in 10 mL DMF for 10 min then washed with 3 x DMF and 2 x DCM. The palmitoleoylated, disulphide-bridged peptide was cleaved from the resin and protecting groups removed by addition of a cleavage solution (95% TFA, 2.5% H₂O, 2.5% TIS). After 1 h, the resin was removed by filtration and peptides were precipitated with diethyl ether on ice. The peptide

901 was isolated by centrifugation, then dissolved in H₂O and freeze dried overnight. Portions of
902 the peptide were purified on a C8 reverse phase HPLC column (Agilent PrepHT Zorbax
903 300SB-C8, 21.2x250 mm, 7 m) using a linear solvent gradient of 20-90% MeCN (0.08%
904 TFA) in H₂O (0.08% TFA) over 40 min at a flow rate of 8 mL/min. The peak fraction was
905 analyzed by LC-MS on an Agilent 1100 LC-MSD. The calculated molecular weight of the
906 peptide was in agreement with the mass found. Calculated MW: 1542.00, actual mass:
907 1541.85.

908

909 • mmWNT7A 201-213 S206 ox C16:1

910 NH₂-K(Cys-S-)HGV(Ser-16:1) GS(Cys-S-)TTKT-COOH

911 Solid phase synthesis took place on an Activotec P-11 peptide synthesizer (Activotec) using a
912 Fmoc-PEG-Biotin NovaTagTM resin (100 µmol; Merck) and N(α)-Fmoc amino acids,
913 including Fmoc-Cys(MMT)-OH, Fmoc-Gly-Ser(ψMe,Mepro)-OH (all Merck) and Boc-
914 Lys(Boc)-OH (Fluorochem). The first Fmoc-Thr(tBu)-OH was double coupled. Boc-
915 Lys(Boc)-OH was incorporated at the N terminal. HATU was used as the coupling reagent
916 with 5- fold excess of amino acids. Following chain assembly, disulphide bridge formation
917 on the resin was performed as follows. Methoxytrityl was removed from the two cysteine
918 residues by treatment of the peptidyl resin for 2 min with 10 ml of 1% TFA, 5% TIS, rest
919 DCM, then washed with DCM. This was repeated 7 times more. Next the peptidyl resin was
920 treated with N-chlorosuccinimide (1 eq) in 10 mL DMF for 10 min then washed with 3 x
921 DMF and 2 x DCM. The disulphide-bridged peptide was cleaved from the resin and
922 protecting groups removed by addition of a cleavage solution (95% TFA, 2.5% H₂O, 2.5%
923 TIS). After 1 h, the resin was removed by filtration and peptides were precipitated with
924 diethyl ether on ice. The peptide was isolated by centrifugation, then dissolved in H₂O and
925 freeze dried overnight. Portions of the peptide were purified on a C8 reverse phase HPLC

column (Agilent PrepHT Zorbax 300SB-C8, 21.2x250 mm, 7 m) using a linear solvent gradient of 10-50% MeCN (0.08% TFA) in H₂O (0.08% TFA) over 40 min at a flow rate of 8 mL/min. The peak fraction was analyzed by LC-MS on an Agilent 1100 LC-MSD. The calculated molecular weight of the peptide was in agreement with the mass found. Calculated MW: 1734.99, actual mass: 1733.99.

Biolayer interferometry

Data were collected with Octet RED96 and Octet RED384 instruments (FortéBio). All steps were performed in 10 mM Tris, 35 mM NaCl, pH 8. Initially, Dip and Read Streptavidin Biosensors (FortéBio) were activated by dipping them in buffer for 10 min before starting the analysis. Sensors were then loaded with 0.05 mg/mL of biotinylated palmitoleoylated and non-palmitoleoylated human Wnt7a peptide. After baseline reference collection in wells containing only buffer, biosensors were dipped in analyte dilution series, before allowing dissociation in the same buffer wells where the baseline reference was collected. Peptide-loaded sensors tested against buffer were used for blank subtraction. Unloaded sensors dipped into the analyte dilution series were used as reference to account for non-specific binding.

Upon reference subtraction, data were analysed by the FortéBio (version 11.1) and SigmaPlot (version 14.0) data analysis software. The model used for curve fitting in kinetic and steady-state analysis was a 1:1 Langmuir binding isotherm model. Data were collected in three independent experiments.

Crystallisation, data collection, and structure determination

Purified proteins were concentrated by ultrafiltration to 3.5 mg/mL and incubated for 16 hours at 4 °C with palmitoleoylated human Wnt7a peptide (resuspended in 10 mM Tris-HCl,

952 pH 8, 35 mM NaCl and added at a final concentration of 5 mM). After incubation, 96-well
953 crystallisation plates were set up at 20 °C using a Cartesian Technologies pipetting robot
954 dispensing nanolitre-scale drops consisting of 100 nl of protein solution and 100 nl of
955 reservoir solution⁴⁰. Crystals appeared after 2 weeks in a variety of conditions with 20%
956 (w/v) PEG4000 as precipitant and different pH values.

957 Prior to crystal freezing, crystals were additionally soaked with palmitoleoylated human
958 Wnt7a peptide resuspended in DMSO, at a final concentration of 1 mM peptide in 10% (v/v)
959 DMSO. The crystals were soaked for 1 hour before flash-cooling by dipping into liquid
960 nitrogen, using mother liquor supplemented with 25% (v/v) glycerol as cryoprotectant.

961 Since initial crystals diffracted at 3 Å with a high degree of anisotropy in the c* dimension,
962 optimization of the crystal growth was performed, designing a two-dimensional
963 pH/precipitant screening matrix (5-9 pH interval using 0.1 M MMT⁴¹ buffer, 15-25% w/v
964 PEG4000 concentration interval). The best diffracting crystals grew in 16.25% (w/v)
965 PEG4000, 0.1 M MMT pH 9.

966 Data were collected at 100 K at Diamond Light Source (Didcot, UK) beamline i04 equipped
967 with an Eiger2 X 16M detector using a wavelength of 0.9795 Å.

968 Data were processed using Xia2⁴², scaled using DIALS⁴³ and merged using AIMLESS^{44,45}.

969 The structure of Dlp^{core} in complex with hWnt7a palmitoylated peptide was solved to a
970 resolution of 2.21 Å by molecular replacement with PHASER⁴⁶ using the previously
971 published apo-form of Dlp (PDB ID: 3odn)²³ as a search model. Iterative cycles of
972 refinement and manual rebuilding were performed using phenix.refine⁴⁷ and COOT⁴⁸. To
973 avoid model bias, the Wnt7a peptide model was added only at the latest stages of refinement.

974 PEG was also present in the crystallisation cocktail, however a number of reasons provided
975 the rationale for fitting palmitoleate into the density: several types of omit maps, generated
976 using phenix.refine and phenix.polder (see Fig. 3c and Extended Data Figure 8), show clear

977 evidence of continuous electron density not only for the lipid part but also for the peptide
978 moiety of the palmitoleoylated peptide; although crystallized in a different space group, PEG
979 was also present in the crystallization cocktail of the published apo form and no
980 conformational rearrangement and no lipid-like density is present in the latter; to fit the
981 electron density, a fragment of PEG of the exact same dimensions as the palmitoleate would
982 be required; the highly hydrophobic binding cavity is less compatible with a polar molecule
983 like PEG than with a lipid. Subsequent results for mutant Dlps showing reduced *in vitro* and
984 *in vivo* lipid binding confirmed the identification of the pocket as the palmitoleate binding
985 unit.

986 SMILES for the chemical structure of the peptide was designed using CHEMDRAW and
987 peptide model and restraints for refinement were generated by the GRADE webserver⁴⁹.
988 Refinement models were validated with MOLPROBITY⁵⁰. No Ramachandran outliers are
989 present in the final model, with 97.83% of the residues in the favoured region of the
990 Ramachandran plot. Data collection and refinement statistics are presented in Extended Data
991 Table 1.

992 Inspection of crystal contacts revealed one in the region of the conformational change,
993 however PISA (Protein Interfaces, Surfaces and Assemblies, EMBL-EBI⁵¹ server analysis
994 reported this to be only a minor interface (554 Å² out of 22260 Å² of accessible surface area),
995 with a CSS (Complex Significance Score) of 0, indicating that it is an energetically very
996 weak interface and therefore not be expected to trigger a significant conformational
997 rearrangement in the structure. Structural superpositions were performed in COOT, using the
998 LSQ algorithm. Structural figures were created by PYMOL (v.2.2.0) and assembled using
999 INKSCAPE. Sequence alignments were generated using JALVIEW⁵² (v. 2.10.5). Lipid-
1000 binding cavity analysis and visualization were performed using CASTp⁵³ and its related
1001 PYMOL plugin.

1002

1003 **Large-scale expression and purification of mutants for *in vitro* binding analysis**

1004 Mutations were generated by a two-step overlapping PCR and mutants were cloned into the
1005 pHLSec vector encoding for C-terminal 6xHis and AviTagTM tags⁵⁴. The mutant Dlp forms
1006 were expressed by transient transfection of GnTI(-) HEK293S, dialyzed against 20 mM Tris,
1007 pH 8, 500 mM NaCl, 20 mM imidazole and initially purified by Ni-NTA affinity
1008 chromatography (HisTrap HP, GE Healthcare). Subsequently, proteins were further purified
1009 by SEC using the same experimental setting described for the wild-type protein.

1010

1011 **Protein – lipid binding tests by Fluorescence detection size exclusion chromatography**
1012 **(FSEC)**

1013 Fluorescently-labelled C16:0 palmitic acid BODIPYTM FL C₁₆ (4,4-Difluoro-5,7-Dimethyl-4-
1014 Bora-3a,4a-Diaza-s-Indacene-3-Hexadecanoic Acid, Sigma-Aldrich) was incubated with the
1015 proteins of interest for 16 hours at 4 °C in 10 mM Tris-HCl, pH 8, 35 mM NaCl, 7.5%
1016 DMSO. The proteins were used at a concentration of 2 uM, and the fluorescent lipid was
1017 added at a 1:20 (w/w) protein:lipid ratio. The runs were performed at a flow rate of 0.08
1018 ml/min.

1019 After incubation, the samples were run on a Superose 6 Increase 3.2/200 column in a FSEC
1020 Prominence HPLC system (Shimadzu) equipped with a RF-10AXL fluorescent detector. The
1021 running buffer was 10 mM Tris-HCl, pH 8, 35 mM NaCl. The fluorescent dye was excited at
1022 505 nM and emission registered at 512 nM; absorbance at 280 nM was also registered to
1023 compare the elution profiles with those of the fluorescence emission. BODIPYTM FL C₁₆ in
1024 absence of proteins was run as control. Data were collected in three independent experiments.

1025

1026

1027

1028

1029

1030

1031

1032
1033

ADDITIONAL REFERENCES

- 1034 34 Port, F., Chen, H. M., Lee, T. & Bullock, S. L. Optimized CRISPR/Cas tools for
1035 efficient germline and somatic genome engineering in *Drosophila*. *Proc Natl Acad Sci*
1036 *U S A* **111**, E2967-2976, doi:10.1073/pnas.1405500111 (2014).
- 1037 35 Liebschner, D. *et al.* Polder maps: improving OMIT maps by excluding bulk solvent.
1038 *Acta Crystallogr D Struct Biol* **73**, 148-157, doi:10.1107/S2059798316018210
1039 (2017).
- 1040 36 Elegheert, J. *et al.* Lentiviral transduction of mammalian cells for fast, scalable and
1041 high-level production of soluble and membrane proteins. *Nat Protoc* **13**, 2991-3017,
1042 doi:10.1038/s41596-018-0075-9 (2018).
- 1043 37 Reeves, P. J., Callewaert, N., Contreras, R. & Khorana, H. G. Structure and function
1044 in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-
1045 glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative
1046 HEK293S stable mammalian cell line. *Proc Natl Acad Sci U S A* **99**, 13419-13424,
1047 doi:10.1073/pnas.212519299 (2002).
- 1048 38 Aricescu, A. R., Lu, W. & Jones, E. Y. A time- and cost-efficient system for high-
1049 level protein production in mammalian cells. *Acta Crystallogr D Biol Crystallogr* **62**,
1050 1243-1250, doi:10.1107/S0907444906029799 (2006).
- 1051 39 Chang, V. T. *et al.* Glycoprotein structural genomics: solving the glycosylation
1052 problem. *Structure* **15**, 267-273, doi:10.1016/j.str.2007.01.011 (2007).
- 1053 40 Walter, T. S. *et al.* A procedure for setting up high-throughput nanolitre
1054 crystallization experiments. Crystallization workflow for initial screening, automated
1055 storage, imaging and optimization. *Acta Crystallogr D Biol Crystallogr* **61**, 651-657,
1056 doi:10.1107/S0907444905007808 (2005).
- 1057 41 Newman, J. Novel buffer systems for macromolecular crystallization. *Acta*
1058 *Crystallogr D Biol Crystallogr* **60**, 610-612, doi:10.1107/S0907444903029640
1059 (2004).
- 1060 42 Winter, G., Lobley, C. M. & Prince, S. M. Decision making in xia2. *Acta Crystallogr*
1061 *D Biol Crystallogr* **69**, 1260-1273, doi:10.1107/S0907444913015308 (2013).
- 1062 43 Winter, G. *et al.* DIALS: implementation and evaluation of a new integration
1063 package. *Acta Crystallogr D Struct Biol* **74**, 85-97, doi:10.1107/S2059798317017235
1064 (2018).
- 1065 44 Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution?
1066 *Acta Crystallogr D Biol Crystallogr* **69**, 1204-1214,
1067 doi:10.1107/S0907444913000061 (2013).
- 1068 45 Winn, M. D. *et al.* Overview of the CCP4 suite and current developments. *Acta*
1069 *Crystallogr D Biol Crystallogr* **67**, 235-242, doi:10.1107/S0907444910045749
1070 (2011).
- 1071 46 McCoy, A. J. *et al.* Phaser crystallographic software. *J Appl Crystallogr* **40**, 658-674,
1072 doi:10.1107/S0021889807021206 (2007).
- 1073 47 Afonine, P. V. *et al.* Towards automated crystallographic structure refinement with
1074 phenix.refine. *Acta Crystallogr D Biol Crystallogr* **68**, 352-367,
1075 doi:10.1107/S0907444912001308 (2012).
- 1076 48 Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of
1077 Coot. *Acta Crystallogr D Biol Crystallogr* **66**, 486-501,
1078 doi:10.1107/S0907444910007493 (2010).
- 1079 49 Smart, O. S. Grade v. 1.105, <<http://grade.globalphasing.org>>. (2012).

1080 50 Williams, C. J. *et al.* MolProbity: More and better reference data for improved all-
 1081 atom structure validation. *Protein Sci* **27**, 293-315, doi:10.1002/pro.3330 (2018).
 1082 51 Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline
 1083 state. *J Mol Biol* **372**, 774-797, doi:10.1016/j.jmb.2007.05.022 (2007).
 1084 52 Waterhouse, A. M., Procter, J. B., Martin, D. M., Clamp, M. & Barton, G. J. Jalview
 1085 Version 2--a multiple sequence alignment editor and analysis workbench.
 1086 *Bioinformatics* **25**, 1189-1191, doi:10.1093/bioinformatics/btp033 (2009).
 1087 53 Tian, W., Chen, C., Lei, X., Zhao, J. & Liang, J. CASTp 3.0: computed atlas of
 1088 surface topography of proteins. *Nucleic Acids Res* **46**, W363-W367,
 1089 doi:10.1093/nar/gky473 (2018).
 1090 54 Beckett, D., Kovaleva, E. & Schatz, P. J. A minimal peptide substrate in biotin
 1091 holoenzyme synthetase-catalyzed biotinylation. *Protein Sci* **8**, 921-929,
 1092 doi:10.1110/ps.8.4.921 (1999).
 1093
 1094